News Related to CLR125

Related coverage linked through entity extraction aliases.

Cellectar expands IP estate and raises up to $140 million for iopofosine I 131

May 05, 2026

Cellectar Biosciences expanded its global IP estate and announced oversubscribed financing of up to $140 million. The funding supports iopofosine I 131 regulatory filings and a confirmatory study in Waldenström macroglobulinemia.

Cellectar Biosciences Sets March 4 Date for Full-Year 2025 Results and Corporate Update

Feb 25, 2026

Cellectar Biosciences said it will report full-year 2025 financial results and provide a corporate update on March 4, 2026. The company also shared conference call, webcast, and replay details.